Treatment precursor stadia of anal cancer with Efudix-cream in HIV positive homosexual me
Recruiting
- Conditions
- Anale intraepitheliale neoplasia in HIV-positive patients
- Registration Number
- NL-OMON28276
- Lead Sponsor
- - Academic Medical Center (AMC)- St. Josef Hospital, Ruhr Universität, Bochum
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
1. Patient is >18 years of age
2. Patient has a proven HIV infection
Exclusion Criteria
1. History of anal carcinoma
2 .History of chronic bowel disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Histological resolution of AIN<br /><br>- Relapse rate at 6 and 12 months
- Secondary Outcome Measures
Name Time Method - Side effects of treatment <br /><br>- HPV types and load before and after treatment
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie 5-Fluorouracil's efficacy in treating anal intraepithelial neoplasia in HIV-positive MSM?
How does 5-Fluorouracil cream compare to standard-of-care therapies like imiquimod for AIN in HIV-positive patients?
Which biomarkers correlate with response to 5-Fluorouracil in anal dysplasia treatment among HIV-positive men who have sex with men?
What are the most common adverse events associated with 5-Fluorouracil cream in HIV-positive AIN patients and their management strategies?
Are there combination therapies involving 5-Fluorouracil and immune checkpoint inhibitors for high-grade anal squamous intraepithelial lesions in HIV populations?